Alpha-lipoic acid for diabetic peripheral neuropathy
CONCLUSIONS: Our analysis suggests that ALA probably has little or no effect on neuropathy symptoms or adverse events at six months, and may have little or no effect on impairment at six months. All the studies were at high risk of attrition bias. Therefore, future RCTs should ensure complete follow-up and transparent reporting of any participants missing from the analyses.PMID:38205823 | PMC:PMC10782777 | DOI:10.1002/14651858.CD012967.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Cristian Baicus Adrian Purcarea Erik von Elm Caterina Delcea Florentina L Furtunescu Source Type: research
More News: Brain | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | General Medicine | Neurology | Peripheral Neuropathy | Study